{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-003608","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2022-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.129586+00:00","generated_at":"2026-06-27T12:40:35.630974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arrowhead Q1 net loss widens to $0.60/share; GSK licenses NASH candidate","bullets":["Net loss of $62.9M ($0.60 diluted EPS) vs $20.7M ($0.20) in prior year quarter.","Revenue rose to $27.4M from $21.3M, primarily from license and collaboration revenue.","R&D expense nearly doubled to $65.8M; G&A expense tripled to $25.0M.","Initiated PALISADE Phase 3 study for ARO-APOC3 in familial chylomicronemia syndrome.","Entered exclusive license with GSK for ARO-HSD (NASH); advanced two pulmonary candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-003608","json":"https://secwatch.observer/filing/0001564590-22-003608.json","markdown":"https://secwatch.observer/filing/0001564590-22-003608.md","text":"https://secwatch.observer/filing/0001564590-22-003608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000156459022003608/0001564590-22-003608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000156459022003608/arwr-8k_20220202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:40:35.630974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}